20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and
tolerability of orally administered AKB-6548 in patients with Chronic Kidney Disease
(pre-dialysis) with anemia with dosing for 20 weeks.